EUCRISA®

Drug Information Related Patent
Hold Company
ANACOR PHARMS INC
Dosage and Administration
OINTMENT;TOPICAL
Specification
2%
Indication
EUCRISA® is indicated for topical treatment of mild to moderate atopic dermatitis in adults and in pediatric patients 3 months of age and older.
API
CRISABOROLE
API Structure
Drug Patent
Patent NoExpiration Date
80394512029/6/29
8039451*PED2029/12/29
81686142030/1/20
8168614*PED2030/7/20
85017122027/2/16
8501712*PED2027/8/16
96820922027/2/16
9682092*PED2027/8/16
API Patent
Patent NoExpiration Date
80394512029/6/29
8039451*PED2029/12/29
81686142030/1/20
8168614*PED2030/7/20
85017122027/2/16
8501712*PED2027/8/16
96820922027/2/16
9682092*PED2027/8/16
HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

CONTACT US
  • Tel:
  • E-mail:
  • Address:
  • WhatsAPP
    WhatsAPP
Privacy Policy | Cookie Policy
Copyright © Protheragen-ING. All Rights Reserved.
Member of
dcat
CERTIFICATION
dcat
dcat dcat dcat dcat
Top